These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 31836320)

  • 1. Anti-tumour necrosis factor-α therapy and recurrent or new primary cancers in patients with inflammatory bowel disease, rheumatoid arthritis, or psoriasis and previous cancer in Denmark: a nationwide, population-based cohort study.
    Waljee AK; Higgins PDR; Jensen CB; Villumsen M; Cohen-Mekelburg SA; Wallace BI; Berinstein JA; Allin KH; Jess T
    Lancet Gastroenterol Hepatol; 2020 Mar; 5(3):276-284. PubMed ID: 31836320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Absolute and Relative Risk of New-Onset Psoriasis Associated With Tumor Necrosis Factor-α Inhibitor Treatment in Patients With Immune-Mediated Inflammatory Diseases: A Danish Nationwide Cohort Study.
    Thein D; Egeberg A; Skov L; Loft N
    JAMA Dermatol; 2022 Sep; 158(9):997-1004. PubMed ID: 35767240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of tumour necrosis factor-α inhibitors and the risk of serious infection in paediatric inflammatory bowel disease in Denmark: a nationwide cohort study.
    Wintzell V; Svanström H; Melbye M; Jess T; Olén O; Ludvigsson JF; Pasternak B
    Lancet Gastroenterol Hepatol; 2019 Nov; 4(11):845-853. PubMed ID: 31494100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased risk of developing Crohn's disease or ulcerative colitis in 17 018 patients while under treatment with anti-TNFα agents, particularly etanercept, for autoimmune diseases other than inflammatory bowel disease.
    Korzenik J; Larsen MD; Nielsen J; Kjeldsen J; Nørgård BM
    Aliment Pharmacol Ther; 2019 Aug; 50(3):289-294. PubMed ID: 31267570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association Between Breast Cancer Recurrence and Immunosuppression in Rheumatoid Arthritis and Inflammatory Bowel Disease: A Cohort Study.
    Mamtani R; Clark AS; Scott FI; Brensinger CM; Boursi B; Chen L; Xie F; Yun H; Osterman MT; Curtis JR; Lewis JD
    Arthritis Rheumatol; 2016 Oct; 68(10):2403-11. PubMed ID: 27159030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor Necrosis Factor Inhibitors in Inflammatory Bowel Disease and Risk of Immune Mediated Inflammatory Diseases.
    Ward D; Nyboe Andersen N; Gørtz S; Thorn Iversen A; Højgaard Allin K; Beaugerie L; Kirchgesner J; Jess T
    Clin Gastroenterol Hepatol; 2024 Jan; 22(1):135-143.e8. PubMed ID: 37442315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of Biologic Therapy in Older Patients With Immune-Mediated Diseases: A Systematic Review and Meta-analysis.
    Borren NZ; Ananthakrishnan AN
    Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1736-1743.e4. PubMed ID: 30616024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of Immune-Mediated Inflammatory Diseases Among Patients With Inflammatory Bowel Diseases in Denmark.
    Burisch J; Jess T; Egeberg A
    Clin Gastroenterol Hepatol; 2019 Dec; 17(13):2704-2712.e3. PubMed ID: 30936024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between tumor necrosis factor-α antagonists and risk of cancer in patients with inflammatory bowel disease.
    Nyboe Andersen N; Pasternak B; Basit S; Andersson M; Svanström H; Caspersen S; Munkholm P; Hviid A; Jess T
    JAMA; 2014 Jun; 311(23):2406-13. PubMed ID: 24938563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19.
    Izadi Z; Brenner EJ; Mahil SK; Dand N; Yiu ZZN; Yates M; Ungaro RC; Zhang X; Agrawal M; Colombel JF; Gianfrancesco MA; Hyrich KL; Strangfeld A; Carmona L; Mateus EF; Lawson-Tovey S; Klingberg E; Cuomo G; Caprioli M; Cruz-Machado AR; Mazeda Pereira AC; Hasseli R; Pfeil A; Lorenz HM; Hoyer BF; Trupin L; Rush S; Katz P; Schmajuk G; Jacobsohn L; Seet AM; Al Emadi S; Wise L; Gilbert EL; Duarte-García A; Valenzuela-Almada MO; Isnardi CA; Quintana R; Soriano ER; Hsu TY; D'Silva KM; Sparks JA; Patel NJ; Xavier RM; Marques CDL; Kakehasi AM; Flipo RM; Claudepierre P; Cantagrel A; Goupille P; Wallace ZS; Bhana S; Costello W; Grainger R; Hausmann JS; Liew JW; Sirotich E; Sufka P; Robinson PC; Machado PM; Griffiths CEM; Barker JN; Smith CH; Yazdany J; Kappelman MD; ;
    JAMA Netw Open; 2021 Oct; 4(10):e2129639. PubMed ID: 34661663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pregnancy and neonatal outcomes in women with immune mediated inflammatory diseases exposed to anti-tumor necrosis factor-α during pregnancy: A systemic review and meta-analysis.
    Barenbrug L; Groen MT; Hoentjen F; van Drongelen J; Reek JMPAVD; Joosten I; de Jong EMGJ; van der Molen RG
    J Autoimmun; 2021 Aug; 122():102676. PubMed ID: 34126302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients.
    Wollina U; Hansel G; Koch A; Schönlebe J; Köstler E; Haroske G
    Am J Clin Dermatol; 2008; 9(1):1-14. PubMed ID: 18092839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Demyelinating Events Following Initiation of Anti-TNFα Therapy in the British Society for Rheumatology Biologics Registry in Rheumatoid Arthritis.
    Taylor TRP; Galloway J; Davies R; Hyrich K; Dobson R
    Neurol Neuroimmunol Neuroinflamm; 2021 May; 8(3):. PubMed ID: 33863839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Earlier discontinuation of TNF-α inhibitor therapy in female patients with inflammatory bowel disease is related to a greater risk of side effects.
    Schultheiss JPD; Brand EC; Lamers E; van den Berg WCM; van Schaik FDM; Oldenburg B; Fidder HH
    Aliment Pharmacol Ther; 2019 Aug; 50(4):386-396. PubMed ID: 31310690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of neuroinflammatory events in arthritis patients treated with tumour necrosis factor alpha inhibitors: a collaborative population-based cohort study from Denmark and Sweden.
    Kopp TI; Delcoigne B; Arkema EV; Jacobsen RK; Magyari M; Ibfelt EH; Locht H; Sellebjerg F; Cordtz RL; Jensen DV; Askling J; Dreyer L
    Ann Rheum Dis; 2020 May; 79(5):566-572. PubMed ID: 32161058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between tumour necrosis factor-α inhibitors and risk of serious infections in people with inflammatory bowel disease: nationwide Danish cohort study.
    Nyboe Andersen N; Pasternak B; Friis-Møller N; Andersson M; Jess T
    BMJ; 2015 Jun; 350():h2809. PubMed ID: 26048617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence of psoriasiform diseases secondary to tumour necrosis factor antagonists in patients with inflammatory bowel disease: a nationwide population-based cohort study.
    Bae JM; Lee HH; Lee BI; Lee KM; Eun SH; Cho ML; Kim JS; Park JM; Cho YS; Lee IS; Kim SW; Choi H; Choi MG
    Aliment Pharmacol Ther; 2018 Jul; 48(2):196-205. PubMed ID: 29869804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Do tumor necrosis factor inhibitors increase cancer risk in patients with chronic immune-mediated inflammatory disorders?
    Chen Y; Friedman M; Liu G; Deodhar A; Chu CQ
    Cytokine; 2018 Jan; 101():78-88. PubMed ID: 27688201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden.
    Raaschou P; Simard JF; Holmqvist M; Askling J;
    BMJ; 2013 Apr; 346():f1939. PubMed ID: 23568792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.
    Smolen JS; Kay J; Doyle MK; Landewé R; Matteson EL; Wollenhaupt J; Gaylis N; Murphy FT; Neal JS; Zhou Y; Visvanathan S; Hsia EC; Rahman MU;
    Lancet; 2009 Jul; 374(9685):210-21. PubMed ID: 19560810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.